# **Special Issue**

# Innovative Approaches to GABAergic Drug Discovery: From Molecular Mechanisms to Advanced Therapeutics

# Message from the Guest Editors

This Special Issue invites contributions that elucidate the latest findings in disease-related target discovery. drug development, and pharmaceutical innovations. We welcome studies that examine the synergies among chemistry, biology, and pharmaceutical sciences. including biomarker identification, target validation, and drug design. We particularly encourage work that employs methodologies such as artificial intelligence, machine learning, structural bioinformatics, and highthroughput screening. A focal area of interest is the role of neurotransmitter systems, especially gammaaminobutyric acid (GABA), in drug development. GABAergic modulation is critical in various neurological and psychiatric disorders, including epilepsy, anxiety, and neurodegenerative diseases. Investigating GABAtargeting drugs and receptor interactions can lead to more precise and effective therapeutic interventions. Furthermore, we encourage research on advanced carriers, including nanoparticles, liposomes, and polymer-based systems designed for controlled release and improved solubility.

## **Guest Editors**

Dr. Wojciech Kołodziejczyk

Department of Chemistry, Physics and Atmospheric Sciences, Jackson State University, Jackson, MS 39217, USA

Dr. Donato Colangelo

Department of Health Sciences, Università del Piemonte Orientale UPO, 28100 Novara, Italy

## Deadline for manuscript submissions

25 October 2025



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/236227

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

